Statement of Changes in Beneficial Ownership (4)
May 26 2020 - 5:14PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
BAUMGARTNER ROBERT V |
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp
[
TECH
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
|
|
(Last)
(First)
(Middle)
5775 WAYZATA BOULEVARD, SUITE 400 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
5/21/2020 |
|
(Street)
MINNEAPOLIS, MN 55416
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
| Common Stock | 5/21/2020 | | M | | 5000 | A | $70.35 | 14221 | D |
|
| Common Stock | 5/21/2020 | | S | | 1300 | D | $265.3537 (1) | 12921 | D |
|
| Common Stock | 5/21/2020 | | S | | 1601 | D | $266.0706 (2) | 11320 | D |
|
| Common Stock | 5/21/2020 | | S | | 1974 | D | $267.3178 (3) | 9346 | D |
|
| Common Stock | 5/21/2020 | | S | | 125 | D | $267.9406 (4) | 9221 | D |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Options (right to Buy) | $70.35 | 5/21/2020 | | M | | | 5000 | 10/27/2011 | 10/26/2021 | Common Stock | 5000 | $0 | 0 | D |
|
| Stock Options (right to buy) | $66.90 | | | | | | | 10/25/2012 | 10/24/2022 | Common Stock | 5000 | | 5000 | D |
|
| Stock Options (right to buy) | $87.39 | | | | | | | 10/31/2013 | 10/30/2023 | Common Stock | 4000 | | 4000 | D |
|
| Stock Options (right to buy) | $91.78 | | | | | | | 10/30/2014 | 10/30/2024 | Common Stock | 4000 | | 4000 | D |
|
| Stock Options (right to buy) | $87.34 | | | | | | | 10/29/2016 | 10/28/2025 | Common Stock | 4260 | | 4260 | D |
|
| Stock Options (right to buy) | $101.19 | | | | | | | 10/26/2017 | 10/26/2026 | Common Stock | 3985 | | 3985 | D |
|
| Stock Options (right to buy) | $125.05 | | | | | | | 10/25/2018 | 10/26/2027 | Common Stock | 3125 | | 3125 | D |
|
| Stock Options (right to buy) | $179.84 | | | | | | | 10/24/2019 | 10/25/2028 | Common Stock | 1898 | | 1898 | D |
|
| Stock Options (right to buy) | $201.64 | | | | | | | (5) | 10/24/2029 | Common Stock | 2011 | | 2011 | D |
|
| Explanation of Responses: |
| (1) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $264.64 to $265.6276, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| (2) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.68 to $266.6712, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| (3) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.82 to $267.80, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| (4) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.82 to $267.97, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| (5) | The option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of Bio-Techne's 2020 annual meeting of shareholders. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
BAUMGARTNER ROBERT V
5775 WAYZATA BOULEVARD, SUITE 400
MINNEAPOLIS, MN 55416 | X |
|
|
|
Signatures
|
| /s/ Brenda S. Furlow as Attorney-in-Fact for Robert V. Baumgartner pursuant to Power of Attorney previously filed. | | 5/26/2020 |
| **Signature of Reporting Person | Date |
Bio Techne (NASDAQ:TECH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bio Techne (NASDAQ:TECH)
Historical Stock Chart
From Apr 2023 to Apr 2024
